A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA)
C. Wainwright, C. Nakamura, D. Geller, A.B. MontgomeryVolume:
9
Year:
2010
Language:
english
DOI:
10.1016/s1569-1993(10)60082-3
File:
PDF, 53 KB
english, 2010